A phase 1 study of a vaccine targeting preferentially expressed antigen in melanoma and prostate-specific membrane antigen in patients with advanced solid tumors.
about
Therapeutic cancer vaccines: past, present, and futurePreclinical and clinical development of DNA vaccines for prostate cancer.Expression of cancer-testis antigens MAGEA1, MAGEA3, ACRBP, PRAME, SSX2, and CTAG2 in myxoid and round cell liposarcoma.Intralymphatic immunotherapyRates of MAGE-A3 and PRAME expressing tumors in FFPE tissue specimens from bladder cancer patients: potential targets for antigen-specific cancer immunotherapeutics.DNA vaccines, electroporation and their applications in cancer treatmentA Comprehensive Preclinical Model Evaluating the Recombinant PRAME Antigen Combined With the AS15 Immunostimulant to Fight Against PRAME-expressing TumorsCancer treatment using peptides: current therapies and future prospectsNew routes for allergen immunotherapy.Therapeutic cancer vaccines in prostate cancer: the quest for intermediate markers of response.Induction of cancer testis antigen expression in circulating acute myeloid leukemia blasts following hypomethylating agent monotherapy.Combining T-cell immunotherapy and anti-androgen therapy for prostate cancer.Epigenetic reprogramming and aberrant expression of PRAME are associated with increased metastatic risk in Class 1 and Class 2 uveal melanomas.Influence of human immune cells on cancer: studies at the University of Colorado.Presence of antigen-specific somatic allelic mutations and splice variants do not predict for immunological response to genetic vaccination.Genetic cancer vaccines: current status and perspectives.Prostate cancer vaccines in clinical trials.Prostate cancer vaccines.Evolving role of tumor antigens for future melanoma therapies.Antigen-specific vaccines for cancer treatment.A therapeutic T cell receptor mimic antibody targets tumor-associated PRAME peptide/HLA-I antigens.Altered peptide ligands revisited: vaccine design through chemically modified HLA-A2-restricted T cell epitopesIn vivo immuno-targeting of an extracellular epitope of membrane bound preferentially expressed antigen in melanoma (PRAME).BRAF inhibition improves tumor recognition by the immune system: Potential implications for combinatorial therapies against melanoma involving adoptive T-cell transfer.Novel prostate cancer immunotherapy with a DNA-encoded anti-prostate-specific membrane antigen monoclonal antibody.Immunotherapy advances for mesothelioma treatment.Safety and immunogenicity of the PRAME cancer immunotherapeutic in metastatic melanoma: results of a phase I dose escalation study.
P2860
Q26863283-55BF1ABD-9979-4D81-B378-C9909CF5C550Q33740811-2D3455AD-FC39-476D-8E15-577E8AE50522Q34870799-6EFB1E50-2B78-4B8E-9CE3-671D8AC8921AQ35155423-F4D576DF-F1C7-4632-9EA9-62C6CDA21227Q36095397-7AB23575-F4FD-4FAC-8285-085997AC52DFQ36256459-55386632-0983-4387-8B0E-2564CF965AB4Q36322371-E73198E6-583F-48EC-B64E-05DD4C2BE393Q36515785-E1839C24-5231-4086-AAA4-54AFC4897FACQ36864957-796FAECC-145E-4AB5-B7B6-C5E3EF4411B2Q37017101-BA5B04C2-6D90-4FE0-AF47-930BEFBB4E70Q37022306-710D47C7-8C48-4EF2-9CD5-E3BF94585006Q37443603-F3DBB207-4BF5-433D-8E10-C3EC8E063940Q37644842-FA6D20ED-980E-467E-88A5-0F1D56D0FBF2Q37698684-D2A8A0B9-3C36-43C0-B9B1-8057389311A6Q37703163-E515F2A7-8820-4945-978F-A87EC487E774Q38009352-2F800A69-5874-4BD2-A317-38A447C37C23Q38036690-CD1C58FA-4AA2-4F08-AC09-2B51E97FA46BQ38089935-03E9523A-B684-4C04-8685-6213B73EEAB5Q38232855-BCE4AEA2-B8BF-4C55-95E0-E5EDF5FB6B63Q38284692-1997543F-03B5-4869-980B-38FE35D8C213Q38719407-11FC719E-23E4-4111-9482-E4CF96EDB051Q41703140-3C83DCC4-E037-44E9-ACD5-EF9B8B4B09DCQ42371595-C02043E0-120B-4297-A688-2B5E14B4CA93Q42417533-DCAC3EC0-4EDB-4EED-8682-FF38B8061AAAQ47936907-4FDEF92B-580A-4B0E-A543-EAE4FA22EB4EQ51823843-868CEDDB-AFE2-4385-B0C8-9C64F5E9241DQ54945635-EBE90021-FE5A-45A5-A630-6874790A805A
P2860
A phase 1 study of a vaccine targeting preferentially expressed antigen in melanoma and prostate-specific membrane antigen in patients with advanced solid tumors.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on September 2011
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
A phase 1 study of a vaccine t ...... ts with advanced solid tumors.
@en
A phase 1 study of a vaccine t ...... ts with advanced solid tumors.
@nl
type
label
A phase 1 study of a vaccine t ...... ts with advanced solid tumors.
@en
A phase 1 study of a vaccine t ...... ts with advanced solid tumors.
@nl
prefLabel
A phase 1 study of a vaccine t ...... ts with advanced solid tumors.
@en
A phase 1 study of a vaccine t ...... ts with advanced solid tumors.
@nl
P2093
P2860
P1476
A phase 1 study of a vaccine t ...... ts with advanced solid tumors.
@en
P2093
Adrian Bot
Dar Rosario
David C Diamond
Jeffrey S Weber
John L Marshall
Lee D Cranmer
Marc S Ernstoff
Mihail Obrocea
Nicholas J Vogelzang
Oscar B Goodman
P2860
P304
P356
10.1097/CJI.0B013E3182280DB1
P577
2011-09-01T00:00:00Z